Patents by Inventor Jeremy Schulenburg York

Jeremy Schulenburg York has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180250282
    Abstract: The present invention provides compounds of Formula 1, or a pharmaceutically acceptable salt thereof, where R, R1, and G are as described herein; methods of preparing the compounds; and use of the compounds to treat pain and/or inflammation associated with arthritis or osteoarthritis.
    Type: Application
    Filed: May 7, 2018
    Publication date: September 6, 2018
    Inventors: Matthew Joseph Fisher, Steven Lee Kuklish, Peter Rudolph Manninen, Katherine Marie Partridge, Matthew Allen Schiffler, Alan M. Warshawsky, Jeremy Schulenburg York
  • Publication number: 20180251446
    Abstract: The present invention provides compounds of Formula 1, or a pharmaceutically acceptable salts, thereof, where R, X, A, E, and G are as described herein, methods of preparing the compounds, and use of the compounds to treat pain and/or inflammation.
    Type: Application
    Filed: May 8, 2018
    Publication date: September 6, 2018
    Inventors: Matthew Joseph Fisher, Steven Lee Kuklish, Katherine Marie Partridge, Jeremy Schulenburg York
  • Patent number: 10005721
    Abstract: The present invention provides a compound of the Formula I: wherein A is: and W, Y, X, R1, R2, R3, and R4 are as defined herein, or a pharmaceutically acceptable salt thereof, for use as an inhibitor of the EP4 receptor.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: June 26, 2018
    Assignee: Eli Lilly and Company
    Inventors: Maria Jesus Blanco-Pillado, Peter Rudolph Manninen, Matthew Allen Schiffler, Tatiana Natali Vetman, Alan M Warshawsky, Jeremy Schulenburg York
  • Patent number: 9969714
    Abstract: The present invention provides compounds of Formula 1, or a pharmaceutically acceptable salts, thereof, where R, X, A, E, and G are as described herein, methods of preparing the compounds, and use of the compounds to treat pain and/or inflammation.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: May 15, 2018
    Assignee: Eli Lilly and Company
    Inventors: Matthew Joseph Fisher, Steven Lee Kuklish, Katherine Marie Partridge, Jeremy Schulenburg York
  • Patent number: 9962375
    Abstract: The present invention provides compounds of Formula (1), or a pharmaceutically acceptable salt thereof, formula (1), where R, R1, and G are as described herein; methods of preparing the compounds; and use of the compounds to treat pain and/or inflammation associated with arthritis or osteoarthritis.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: May 8, 2018
    Assignee: Eli Lilly and Company
    Inventors: Matthew Joseph Fisher, Steven Lee Kuklish, Peter Rudolph Manninen, Katherine Marie Partridge, Matthew Allen Schiffler, Alan M. Warshawsky, Jeremy Schulenburg York
  • Publication number: 20170326128
    Abstract: The present invention provides compounds of Formula (1), or a pharmaceutically acceptable salt thereof, formula (1), where R, R1, and G are as described herein; methods of preparing the compounds; and use of the compounds to treat pain and/or inflammation associated with arthritis or osteoarthritis.
    Type: Application
    Filed: October 22, 2015
    Publication date: November 16, 2017
    Inventors: Matthew Joseph Fisher, Steven Lee Kuklish, Peter Rudolph Manninen, Katherine Marie Partridge, Matthew Allen Schiffler, Alan M. Warshawsky, Jeremy Schulenburg York
  • Publication number: 20170313679
    Abstract: The present invention provides compounds of Formula 1, or a pharmaceutically acceptable salts, thereof, where R, X, A, E, and G are as described herein, methods of preparing the compounds, and use of the compounds to treat pain and/or inflammation.
    Type: Application
    Filed: October 22, 2015
    Publication date: November 2, 2017
    Inventors: Matthew Joseph Fisher, Steven Lee Kuklish, Katherine Marie Partridge, Jeremy Schulenburg York
  • Patent number: 9776964
    Abstract: The present invention provides a compound of the Formula (I): wherein X, R, R1, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined herein, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: October 3, 2017
    Assignee: Eli Lilly and Company
    Inventors: Matthew Joseph Fisher, Steven Lee Kuklish, Peter Rudolph Manninen, Matthew Allen Schiffler, Alan M Warshawsky, Jeremy Schulenburg York
  • Publication number: 20160272585
    Abstract: The present invention provides a compound of the Formula (I): wherein X, R, R1, R2, R3, R4, R5, R6, R7, R8, and R9 are as defined herein, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 11, 2014
    Publication date: September 22, 2016
    Applicant: ELI LILLY AND COMPANY
    Inventors: Matthew Joseph Fisher, Steven Lee Kuklish, Peter Rudolph Manninen, Matthew Allen Schiffler, Alan M Warshawsky, Jeremy Schulenburg York
  • Publication number: 20160251306
    Abstract: The present invention provides a compound of the Formula I: wherein A is: and W, Y, X, R1, R2, R3, and R4 are as defined herein, or a pharmaceutically acceptable salt thereof, for use as an inhibitor of the EP4 receptor.
    Type: Application
    Filed: December 11, 2014
    Publication date: September 1, 2016
    Inventors: Maria Jesus Blanco-Pillado, Peter Rudolph Manninen, Matthew Allen Schiffler, Tatiana Natali Vetman, Alan M Warshawsky, Jeremy Schulenburg York
  • Patent number: 9402838
    Abstract: The present invention provides a compound of the Formula II: wherein X is: R1 is H, —CN, or F; R2 is H or methyl; R3 is H; and R4 is H, methyl, or ethyl; or R3 and R4 joined together form a cyclopropyl ring; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: August 2, 2016
    Assignee: Eli Lilly and Company
    Inventors: Matthew Allen Schiffler, Jeremy Schulenburg York
  • Patent number: 9371289
    Abstract: The present invention provides a compound of the Formula I: wherein R is H or F; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: June 21, 2016
    Assignee: Eli Lilly and Company
    Inventor: Jeremy Schulenburg York
  • Publication number: 20160052889
    Abstract: The present invention provides a compound of the Formula I: wherein R is H or F; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 9, 2014
    Publication date: February 25, 2016
    Inventor: Jeremy Schulenburg York
  • Publication number: 20150126555
    Abstract: The present invention provides a compound of the Formula II: wherein X is: R1 is H, —CN, or F; R2 is H or methyl; R3 is H; and R4 is H, methyl, or ethyl; or R3 and R4 joined together form a cyclopropyl ring; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 13, 2015
    Publication date: May 7, 2015
    Inventors: Matthew Allen SCHIFFLER, Jeremy Schulenburg YORK
  • Patent number: 8962659
    Abstract: The present invention provides a compound of the Formula II: wherein X is: R1 is H, —CN, or F; R2 is H or methyl; R3 is H; and R4 is H, methyl, or ethyl; or R3 and R4 joined together form a cyclopropyl ring; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: February 24, 2015
    Assignee: Eli Lilly and Company
    Inventors: Matthew Allen Schiffler, Jeremy Schulenburg York
  • Publication number: 20140005226
    Abstract: The present invention provides a compound of the Formula II: wherein X is: R1 is H, —CN, or F; R2 is H or methyl; R3 is H; and R4 is H, methyl, or ethyl; or R3 and R4 joined together form a cyclopropyl ring; or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 20, 2013
    Publication date: January 2, 2014
    Inventors: Matthew Allen SCHIFFLER, Jeremy Schulenburg YORK
  • Patent number: 8252831
    Abstract: The present invention provides compounds of the formula below or pharmaceutical salts thereof, wherein R1, R2 and R3 are as described herein; methods of treating osteoarthritis using the compounds; and a process for preparing the compounds.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: August 28, 2012
    Assignee: Eli Lilly and Company
    Inventors: Steven Lee Kuklish, Matthew Allen Schiffler, Jeremy Schulenburg York
  • Publication number: 20120157506
    Abstract: The present invention provides compounds of the formula below or pharmaceutical salts thereof, wherein R1, R2 and R3 are as described herein; methods of treating osteoarthritis using the compounds; and a process for preparing the compounds.
    Type: Application
    Filed: December 16, 2011
    Publication date: June 21, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Steven Lee Kuklish, Matthew Allen Schiffler, Jeremy Schulenburg York
  • Patent number: 8088776
    Abstract: The present invention discloses novel compounds of Formula I: possessing 11 ?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 ?-HSD type 1 activity.
    Type: Grant
    Filed: April 19, 2007
    Date of Patent: January 3, 2012
    Assignee: Eli Lilly and Company
    Inventors: Thomas Daniel Aicher, Zhaogen Chen, Ronald Jay Hinklin, Gary Alan Hite, Alexei Pavlovych Krasutsky, Renhua Li, Jefferson Ray McCowan, Ashraf Saeed, Nancy June Snyder, James Lee Toth, Owen Brendan Wallace, Leonard Larry Winneroski, Jr., Yanping Xu, Jeremy Schulenburg York
  • Patent number: 7998999
    Abstract: The present invention discloses novel compounds of Formula I: having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: August 16, 2011
    Assignee: Eli Lilly and Company
    Inventors: Owen Brendan Wallace, Yanping Xu, Nancy June Snyder, Jeremy Schulenburg York, Alexei Pavlovych Krasutsky